Integrated Approach to Identify Selective PTP1B Inhibitors Targeting the Allosteric Site

被引:4
作者
Yang, Ying [1 ]
Zhang, Lei [1 ]
Tian, Jinying [2 ]
Ye, Fei [2 ]
Xiao, Zhiyan [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Mat Med, Beijing Key Lab Act Subst Discovery & Druggabil E, Beijing 100050, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Mat Med, Beijing Key Lab New Drug Mech & Pharmacol Evaluat, Beijing 100050, Peoples R China
关键词
TYROSINE-PHOSPHATASE; 1B; PROTEIN; DERIVATIVES; DISCOVERY; BINDING;
D O I
10.1021/acs.jcim.1c00357
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Protein tyrosine phosphatase 1B (PTP1B) is an intractable target for drug discovery due to its conservative and cationic catalytic site. Targeting alternative allosteric sites of PTP1B is a promising strategy to achieve specificity and bioavailability. A hierarchical virtual screening based on a previously identified allosteric site was applied to search for potential PTP1B inhibitors with better pharmacological profiles. Four potent PTP1B inhibitors (H1, H3, H7, and H9) with structures distinct from known inhibitors were identified. Among them, H3 and H9 demonstrated evident selectivity to PTP1B over homologous T-cell protein tyrosine phosphatase (TCPTP) and SHP2. Molecular dynamics simulations and molecular mechanics-generalized Born surface area (MM-GBSA) calculations recognized Phe280, Phe196, Leu192, and Asn193 as key residues responsible for potent allosteric inhibition and excellent PTP selectivity. The results not only expand the structural diversity but also aid the future molecular design of PTP1B allosteric inhibitors.
引用
收藏
页码:4720 / 4732
页数:13
相关论文
共 34 条
  • [1] [Anonymous], 2014, DISCOVERY STUDIO MOD
  • [2] [Anonymous], 2016, MOL OP ENV MOE
  • [3] Trends in kinase drug discovery: targets, indications and inhibitor design
    Attwood, Misty M.
    Fabbro, Doriano
    Sokolov, Aleksandr V.
    Knapp, Stefan
    Schioth, Helgi B.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (11) : 839 - 861
  • [4] CRYSTAL-STRUCTURE OF HUMAN PROTEIN-TYROSINE-PHOSPHATASE 1B
    BARFORD, D
    FLINT, AJ
    TONKS, NK
    [J]. SCIENCE, 1994, 263 (5152) : 1397 - 1404
  • [5] Barr AJ, 2010, FUTURE MED CHEM, V2, P1563, DOI [10.4155/fmc.10.241, 10.4155/FMC.10.241]
  • [6] A WELL-BEHAVED ELECTROSTATIC POTENTIAL BASED METHOD USING CHARGE RESTRAINTS FOR DERIVING ATOMIC CHARGES - THE RESP MODEL
    BAYLY, CI
    CIEPLAK, P
    CORNELL, WD
    KOLLMAN, PA
    [J]. JOURNAL OF PHYSICAL CHEMISTRY, 1993, 97 (40) : 10269 - 10280
  • [7] The Amber biomolecular simulation programs
    Case, DA
    Cheatham, TE
    Darden, T
    Gohlke, H
    Luo, R
    Merz, KM
    Onufriev, A
    Simmerling, C
    Wang, B
    Woods, RJ
    [J]. JOURNAL OF COMPUTATIONAL CHEMISTRY, 2005, 26 (16) : 1668 - 1688
  • [8] Anti-diabetic drugs recent approaches and advancements
    Dowarah, Jayanta
    Singh, Ved Prakash
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (05)
  • [9] Frisch M J, 2004, GAUSSIAN 03 REVISION
  • [10] Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551
    Fukuda, S.
    Ohta, T.
    Sakata, S.
    Morinaga, H.
    Ito, M.
    Nakagawa, Y.
    Tanaka, M.
    Matsushita, M.
    [J]. DIABETES OBESITY & METABOLISM, 2010, 12 (04) : 299 - 306